Active substance
Vinblastine
- SFDA 3
- US FDA 7
- Health Canada 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| VINBLASTINE SULPHATE 10MG-10ML VIAL | 1 mg/ml | Solution for injection · Intravenous use | 5 Vial | SAR 504.55 | Generic · Prescription | HOSPIRA UK LIMITED | Valid |
| ONCOVIN 1MG VIAL+SOLVENT 10ML | 1 mg | Powder and solvent for solution for infusion · Intravenous use | 1 Vial | SAR 47.55 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| VELBE 10MG VIAL+SOLVENT 10ML | 10 mg | powder for solution for injection · Intravenous use | 1 Vial | SAR 49.15 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CASTLEMAN DISEASE; HODGKIN'S LYMPHOMA; IMMUNE THROMBOCYPTOPENIC PUPURA; TESTICULAR CANCER
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VINBLASTINE SULFATE | 10MG/VIAL | injectable · injection | HIKMA PHARMS | Prescription | 9 Apr 1987 |
| VINBLASTINE SULFATE | 1MG/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 29 Apr 1987 |
| VELBAN | 10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | LILLY | Discontinued | 25 Nov 1965 |
| VINBLASTINE SULFATE | 10MG/VIAL | injectable · injection | HOSPIRA | Discontinued | 18 Aug 1987 |
| VINBLASTINE SULFATE | 10MG/VIAL | injectable · injection | ABRAXIS PHARM | Discontinued | |
| VINBLASTINE SULFATE | 1MG/ML | injectable · injection | QUAD PHARMS | Discontinued | |
| VINBLASTINE SULFATE | 10MG/VIAL | injectable · injection | QUAD PHARMS | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VINBLASTINE SULFATE INJECTION | 02183056 | 1 MG / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
| VINBLASTINE SULPHATE INJECTION | 02401460 | 1 MG / ML | SOLUTION · INTRAVENOUS | TEVA CANADA LIMITED |
WHO WHO Model List of Essential Medicines (2025)
- 8.2.1. Cytotoxic medicines · complementary
Other specified gliomas of brain; Anaplastic large cell lymphoma, ALK-negative; Anaplastic large cell lymphoma, ALK-positive; Langerhans cell histiocytosis; Kaposi sarcoma of unspecified primary site; Germ cell tumour of testis; Other specified malignant neoplasms of the ovary; Hodgkin lymphoma
Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.